This conference, presented by the Food and Drug Law Institute,will include topics like: implementation issues with respect to risk evaluation and mitigation strategy (REMS), clinical trials registry, pediatric exclusivity/studies, new protections against counterfeit drugs, direct-to-consumer (DTC) advertising, user fees for drugs and medical devices, citizen petitions, advisory committee conflicts of interest, and other changes in the law.

WilmerHale partner Scott Lassman will be a speaker at this event, presented by FDLI.